Maxim Downgrades Applied DNA Sciences to Hold From Buy

Maxim Downgrades Applied DNA Sciences to Hold From Buy.

MT NewswiresMay 14 19:21

Applied DNA Sciences Is Maintained at Buy by HC Wainwright & Co.

Applied DNA Sciences Is Maintained at Buy by HC Wainwright & Co.

Dow JonesMay 14 00:42

HC Wainwright & Co. Maintains Buy on Applied DNA Sciences, Adjusts Price Target To $7

HC Wainwright & Co. analyst Yi Chen maintains Applied DNA Sciences (NASDAQ:APDN) with a Buy, adjusts target to $7 from $1.5.

BenzingaMay 14 00:32

HC Wainwright & Co. : Maintaining the Applied DNA Sciences (APDN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $1.50 to $7.00.

HC Wainwright & Co. : Maintaining the Applied DNA Sciences (APDN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $1.50 to $7.00.

Zhitong FinanceMay 14 00:31

Applied DNA Sciences Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 159.84% HC Wainwright & Co. $1.5 → $7 Maintains Buy 02/09/2024 -44.32% HC Wainwright & Co. $2 →

BenzingaMay 14 00:30

Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML

STONY BROOK, NY / ACCESSWIRE / May 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, and the Institute of Hematology and Blood Transfusion (ÚH

AccesswireMay 13 20:55